Revvity, Inc. (RVTY)

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Ticker
RVTY
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$16.50B
52-week range
$81.22 - $171.74

Valuation

Share price
$152.52 (close of Nov 18, 2026)
P/E (TTM)
65.68x
Price to book
2.27x
Price to free cash flow
27.94x
Enterprise value
$18.67B
Book value per share
$65.14

Price performance

PeriodChange
1 day+3.20%
5 days-3.62%
1 month-0.08%
3 months+34.08%
6 months+59.74%
Year to date+57.64%
1 year+63.89%
3 years+73.38%
5 years-18.57%
10 years+205.34%
All time+16,444.55%

Short interest

As of
Oct 30, 2026
Short % of float
8.76%
Shares short
6.53M
Days to cover
3.90
Change since prior report
+2.10%
Source
FINRA consolidated short interest

Members of Congress who disclosed RVTY trades

Gilbert Ray Cisneros · Lisa McClain · Robert Bresnahan · April McClain Delaney

Super investors holding RVTY

Henry Ellenbogen (Durable Capital Partners LP) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · Lee Ainslie (Maverick Capital LTD)

Profitability and growth

Return on equity
3.33%
Return on invested capital
3.08%
Return on assets
1.98%
Return on capital employed
3.29%
Gross margin
54.77%
Net margin
8.45%
EBITDA margin
26.68%
Revenue growth
3.67%
Net income growth
-10.79%
Free cash flow growth
-5.95%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.58%
Current ratio
2.65x
Net debt to EBITDA
2.86x

Latest reported year

Period end
Dec 28, 2025
Fiscal year
2025
Revenue
$2.86B
Cost of revenue
$1.29B
Gross profit
$1.56B
EBITDA
$761.98M
Net income
$241.20M
Earnings per share
$2.07
Research and development
$215.84M
Interest expense
$92.19M
Shares outstanding
116.54M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-28$2.86B$1.56B$241.20M$2.07
2024-12-29$2.76B$1.54B$270.38M$2.21
2023-12-31$2.75B$1.54B$693.09M$5.56
2023-01-01$3.31B$1.99B$569.18M$4.51
2022-01-02$3.83B$2.43B$943.16M$8.12
2021-01-03$2.66B$2.11B$727.89M$6.52
2019-12-29$2.88B$1.40B$227.56M$2.06
2018-12-30$2.78B$1.34B$237.93M$2.15
2017-12-31$2.26B$1.07B$292.63M$2.67
2017-01-01$2.12B$1.01B$234.30M$2.14

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-2854.77%8.45%3.33%3.08%
2024-12-2955.81%9.81%3.53%2.85%
2023-12-3155.98%25.20%8.80%2.49%
2023-01-0160.08%17.19%7.71%5.04%
2022-01-0263.59%24.64%13.21%7.70%
2021-01-0379.22%27.33%19.49%11.80%
2019-12-2948.41%7.89%8.09%6.97%
2018-12-3048.27%8.56%9.20%6.81%
2017-12-3147.57%12.97%11.69%3.63%
2017-01-0147.90%11.08%10.88%8.32%

Cash and debt by year

Period endCashDebt
2025-12-28$919.86M$2.63B
2024-12-29$1.16B$3.15B
2023-12-31$913.16M$3.18B
2023-01-01$454.36M$3.92B
2022-01-02$603.32M$4.98B
2021-01-03$387.05M$1.61B
2019-12-29$191.88M$2.06B
2018-12-30$163.11M$1.88B
2017-12-31$202.13M$1.79B
2017-01-01$359.26M$1.05B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-28$509.41M$22.85M
2024-12-29$541.65M$37.81M
2023-12-31$9.90M$41.41M
2023-01-01$594.18M$51.52M
2022-01-02$1.32B$29.68M
2021-01-03$828.54M$26.90M
2019-12-29$287.14M$31.51M
2018-12-30$217.78M$28.77M
2017-12-31$249.36M$25.42M
2017-01-01$318.91M$17.16M

Dividend history

Most recent payment
Oct 23, 2026
Paid in the last twelve months
$0.28
Payment dateDividend per share
2026-10-23$0.07
2026-07-17$0.07
2026-04-17$0.07
2026-01-16$0.07
2025-10-17$0.07
2025-07-18$0.07
2025-04-17$0.07
2025-01-17$0.07

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-03Sep 2026$1.29
2026-08-04Jun 2026$1.23
2026-05-05Mar 2026$1.02
2026-02-02Dec 2025$1.59
2025-10-27Sep 2025$1.14
2025-07-28Jun 2025$1.14
2025-04-28Mar 2025$0.96
2025-01-31Dec 2024$1.36

Filings and sources

Company website
revvity.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Charles River Laboratories International, Inc. (CRL) · Medpace Holdings, Inc. (MEDP) · ICON plc (ICLR) · Labcorp Holdings Inc. (LH) · Quest Diagnostics Inc (DGX) · Mettler-Toledo International Inc (MTD) · Illumina, Inc. (ILMN) · Waters Corp (WAT)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades